BPMC

97.55

6.17% 5.67

Handel nachbörslich: 97.55

Blueprint Medicines Corp (BPMC)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BPMC? Forum Prognose

Schlusskurs vom Vortag:

$91.88

Offen:

$91

24-Stunden-Volumen:

936.97K

Relative Volume:

1.51

Marktkapitalisierung:

$6.11B

Einnahmen:

$362.80M

Nettoeinkommen (Verlust:

$-205.49M

KGV:

-10.61

EPS:

-9.19

Netto-Cashflow:

$-347.59M

1W Leistung:

+16.97%

1M Leistung:

+10.09%

6M Leistung:

-8.99%

1J Leistung:

+63.21%

1-Tages-Spanne:

$91.00

$97.67

1-Wochen-Bereich:

$87.28

$97.67

52-Wochen-Spanne:

$56.74

$121.90

Blueprint Medicines Corp Stock (BPMC) Company Profile

Firmenname

Blueprint Medicines Corp

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

617-374-7580

Adresse

45 SIDNEY STREET, CAMBRIDGE, MA

Mitarbeiter

655

Twitter

@BlueprintMeds

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

BPMC's Discussions on Twitter

Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-10-27	Hochstufung	Oppenheimer	Perform → Outperform
2023-08-21	Bestätigt	Needham	Buy
2023-07-31	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-06-05	Herabstufung	SVB Securities	Market Perform → Underperform
2023-01-03	Hochstufung	Wells Fargo	Underweight → Equal Weight
2022-12-14	Eingeleitet	Needham	Buy
2022-11-02	Herabstufung	Oppenheimer	Outperform → Perform
2022-09-14	Eingeleitet	Berenberg	Buy
2022-07-08	Eingeleitet	Oppenheimer	Outperform
2022-06-27	Eingeleitet	Wells Fargo	Underweight
2022-06-10	Herabstufung	Citigroup	Neutral → Sell
2022-06-01	Hochstufung	Jefferies	Hold → Buy
2022-03-01	Eingeleitet	Citigroup	Neutral
2022-02-17	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-01-25	Hochstufung	Stifel	Hold → Buy
2021-11-19	Fortgesetzt	Morgan Stanley	Equal-Weight
2021-09-30	Fortgesetzt	Stifel	Hold
2021-06-04	Fortgesetzt	Robert W. Baird	Outperform
2021-03-31	Eingeleitet	Credit Suisse	Neutral
2020-12-03	Eingeleitet	Stifel	Hold
2020-11-02	Bestätigt	H.C. Wainwright	Buy
2020-11-02	Herabstufung	Jefferies	Buy → Hold
2020-10-30	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-07-15	Bestätigt	H.C. Wainwright	Buy
2020-05-05	Eingeleitet	Barclays	Equal Weight
2020-03-17	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2020-01-28	Eingeleitet	BMO Capital Markets	Market Perform
2020-01-27	Eingeleitet	BMO Capital Markets	Market Perform
2019-11-06	Hochstufung	Raymond James	Outperform → Strong Buy
2019-10-22	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-03	Eingeleitet	H.C. Wainwright	Buy
2019-09-12	Hochstufung	Raymond James	Mkt Perform → Outperform
2019-08-29	Eingeleitet	Piper Jaffray	Neutral
2019-08-15	Fortgesetzt	Raymond James	Mkt Perform
2019-07-18	Eingeleitet	Deutsche Bank	Buy
2019-05-23	Fortgesetzt	Goldman	Buy
2019-04-03	Eingeleitet	Morgan Stanley	Overweight
2018-09-25	Eingeleitet	Leerink Partners	Outperform
2017-12-11	Bestätigt	Goldman	Buy

Alle ansehen

Blueprint Medicines Corp Aktie (BPMC) Neueste Nachrichten

Nov 04, 2024

Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve

Nov 04, 2024

Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World

Nov 04, 2024

Nov 03, 2024

Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 03, 2024

Nov 02, 2024

Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance

Nov 02, 2024

Nov 01, 2024

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 01, 2024

Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat

Nov 01, 2024

Oct 31, 2024

Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com

Oct 31, 2024

Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024

Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com

Oct 31, 2024

Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024